Thousands of rare diseases affect hundreds of millions of people globally, and hope for treatment is on the rise in the form of cell and gene therapies. While only 9 cell and gene therapies are currently FDA-approved in the U.S., that number is soon expected to grow exponentially. With such drastic change on the horizon, the industry needs to be prepared.
